• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

尼拉帕利与他汀类药物在卵巢癌临床试验中的潜在协同效应。

Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials.

作者信息

Zhang Hailei, Rutkowska Anna, González-Martín Antonio, Mirza Mansoor R, Monk Bradley J, Vergote Ignace, Pothuri Bhavana, Graybill Whitney A Spannuth, Goessel Carsten, Barbash Olena, Bergamini Giovanna, Feng Bin

机构信息

Precision Medicine, R&D, GSK, Waltham, Massachusetts.

Cellzome, a GSK Company, R&D, GSK, Heidelberg, Germany.

出版信息

Cancer Res Commun. 2025 Jan 1;5(1):178-186. doi: 10.1158/2767-9764.CRC-24-0191.

DOI:10.1158/2767-9764.CRC-24-0191
PMID:39636225
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11775730/
Abstract

The presented retrospective analysis suggests, to the best of our knowledge for the first time, a potential significant interaction between statins and niraparib in clinical settings. Nevertheless, further investigations are required to gain a better understanding of the potential clinical benefit.

摘要

据我们所知，此次呈现的回顾性分析首次表明，在临床环境中，他汀类药物与尼拉帕利之间可能存在显著的相互作用。然而，需要进一步研究以更好地了解其潜在的临床益处。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44d9/11775730/334d31b1b429/crc-24-0191_f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44d9/11775730/905afc4650e8/crc-24-0191_f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44d9/11775730/a62d9fe0ba33/crc-24-0191_f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44d9/11775730/ea63684f1b98/crc-24-0191_f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44d9/11775730/334d31b1b429/crc-24-0191_f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44d9/11775730/905afc4650e8/crc-24-0191_f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44d9/11775730/a62d9fe0ba33/crc-24-0191_f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44d9/11775730/ea63684f1b98/crc-24-0191_f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44d9/11775730/334d31b1b429/crc-24-0191_f4.jpg

相似文献

1
Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials.尼拉帕利与他汀类药物在卵巢癌临床试验中的潜在协同效应。
Cancer Res Commun. 2025 Jan 1;5(1):178-186. doi: 10.1158/2767-9764.CRC-24-0191.
2
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.尼拉帕利联合贝伐珠单抗对比尼拉帕利单药用于铂敏感复发性卵巢癌（NSGO-AVANOVA2/ENGOT-ov24）：一项随机、2 期、优效性试验。
Lancet Oncol. 2019 Oct;20(10):1409-1419. doi: 10.1016/S1470-2045(19)30515-7. Epub 2019 Aug 29.
3
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.尼拉帕利用于新诊断的晚期卵巢癌患者的一线维持治疗：PRIMA/ENGOT-OV26/GOG-3012 试验的最终总生存结果。
Ann Oncol. 2024 Nov;35(11):981-992. doi: 10.1016/j.annonc.2024.08.2241. Epub 2024 Sep 14.
4
Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary.随访3.5年的无进展生存期和安全性：新诊断卵巢癌患者尼拉帕利维持治疗的随机3期PRIMA/ENGOT-OV26/GOG-3012试验结果——通俗易懂的总结
Future Oncol. 2024;20(22):1531-1544. doi: 10.2217/fon-2023-0782. Epub 2024 Mar 19.
5
FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy.美国食品和药物管理局批准概要：尼拉帕利用于铂类化疗后缓解的复发性卵巢癌患者的维持治疗。
Clin Cancer Res. 2018 Sep 1;24(17):4066-4071. doi: 10.1158/1078-0432.CCR-18-0042. Epub 2018 Apr 12.
6
Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.尼拉帕利用于 65 岁及以上晚期卵巢癌患者的疗效和安全性：PRIMA/ENGOT-OV26/GOG-3012 试验结果。
Gynecol Oncol. 2024 Aug;187:128-138. doi: 10.1016/j.ygyno.2024.03.009. Epub 2024 Jun 3.
7
Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.尼拉帕利作为维持治疗用于复发性卵巢癌老年患者（≥70 岁）的疗效和安全性：ENGOT-OV16/NOVA 试验的结果。
Gynecol Oncol. 2019 Mar;152(3):560-567. doi: 10.1016/j.ygyno.2018.12.009. Epub 2019 Jan 9.
8
Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer.尼拉帕利和奥拉帕利作为铂类敏感复发性卵巢癌维持治疗的成本效益。
J Manag Care Spec Pharm. 2018 Dec;24(12):1219-1228. doi: 10.18553/jmcp.2018.24.12.1219.
9
Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.尼拉帕利治疗复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌。
Ann Pharmacother. 2020 Oct;54(10):1010-1015. doi: 10.1177/1060028020912749. Epub 2020 Mar 16.
10
Impact of PARP inhibitors on progression-free survival in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective analysis.聚腺苷二磷酸核糖聚合酶抑制剂对铂类敏感复发性上皮性卵巢癌无进展生存期的影响：一项回顾性分析。
World J Surg Oncol. 2024 Oct 21;22(1):276. doi: 10.1186/s12957-024-03562-8.

本文引用的文献

1
Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation.聚（ADP-核糖）聚合酶（PARP）抑制与胆固醇生物合成途径调节的协同效应
Cancer Res Commun. 2024 Sep 1;4(9):2427-2443. doi: 10.1158/2767-9764.CRC-23-0549.
2
Dysregulation of Cholesterol Homeostasis in Ovarian Cancer.卵巢癌中胆固醇稳态的失调
Curr Oncol. 2023 Sep 13;30(9):8386-8400. doi: 10.3390/curroncol30090609.
3
New insights into the therapeutic potentials of statins in cancer.他汀类药物在癌症治疗潜力方面的新见解。
Front Pharmacol. 2023 Jul 7;14:1188926. doi: 10.3389/fphar.2023.1188926. eCollection 2023.
4
Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial.尼拉帕利联合纳武利尤单抗或尼拉帕利联合伊匹单抗治疗铂类敏感型晚期胰腺癌患者的随机、1b/2 期试验。
Lancet Oncol. 2022 Aug;23(8):1009-1020. doi: 10.1016/S1470-2045(22)00369-2. Epub 2022 Jul 7.
5
Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer.超越降脂作用：他汀类药物对心脑血管疾病和癌症的影响
Pharmaceuticals (Basel). 2022 Jan 26;15(2):151. doi: 10.3390/ph15020151.
6
Aberrant Cholesterol Metabolism in Ovarian Cancer: Identification of Novel Therapeutic Targets.卵巢癌中异常的胆固醇代谢：新型治疗靶点的鉴定
Front Oncol. 2021 Nov 8;11:738177. doi: 10.3389/fonc.2021.738177. eCollection 2021.
7
PARPs in lipid metabolism and related diseases.聚腺苷二磷酸核糖聚合酶在脂质代谢及相关疾病中的作用。
Prog Lipid Res. 2021 Nov;84:101117. doi: 10.1016/j.plipres.2021.101117. Epub 2021 Aug 25.
8
Statins: a repurposed drug to fight cancer.他汀类药物：一种用于抗癌的再利用药物。
J Exp Clin Cancer Res. 2021 Jul 24;40(1):241. doi: 10.1186/s13046-021-02041-2.
9
FATTY ACID SYNTHESIS IS REQUIRED FOR BREAST CANCER BRAIN METASTASIS.乳腺癌脑转移需要脂肪酸合成。
Nat Cancer. 2021 Apr;2(4):414-428. doi: 10.1038/s43018-021-00183-y. Epub 2021 Apr 1.
10
Statin use and survival among women with ovarian cancer: an Australian national data-linkage study.使用他汀类药物与卵巢癌患者生存：一项澳大利亚全国数据链接研究。
Br J Cancer. 2021 Aug;125(5):766-771. doi: 10.1038/s41416-021-01460-4. Epub 2021 Jun 16.